B+
Bull case
25%
Probability
Target price
$72.00
+34.7% vs current
XENE
XenonCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$58.00
+8.5% vs current
B-
Bear case
25%
Probability
Target price
$42.00
-21.4% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+54.5
Score
AI commentary
Primary-source evidence improved meaningfully after the March 9, 2026 Phase 3 X-TOLE2 release, but the current setup looks more like a de-risked yet already-recognized epilepsy story than a fresh undiscovered upside case. Xenon now has stronger financing capacity and a stated Q3 2026 NDA target, yet deterministic signals remain modestly negative and current catalyst density is not especially high after the main data event. Net: constructive on asset quality, but cautious on near-term risk/reward unless the company adds regulatory or multi-indication proof beyond what is already public [#PR-2026-03-09] [#PR-2026-03-12] [#10-K-2026-02-26].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-19catalystAAN late-breaking X-TOLE2 presentation on April 19, 2026Medium impact
Management said X-TOLE2 efficacy and safety results will be presented as a late-breaking oral session at AAN on April 19, 2026. With topline efficacy already disclosed, the remaining near-term stock impact likely depends on any added detail around discontinuations, tolerability, and positioning versus prior epilepsy datasets rather than on a new efficacy surprise [#PR-2026-03-09].
2026-09-30eventTargeted U.S. NDA submission for azetukalner in focal onset seizures in Q3 2026High impact
After positive Phase 3 X-TOLE2 topline data, Xenon said it plans to submit an NDA for azetukalner in focal onset seizures in the third quarter of 2026. A clean filing would extend the de-risking arc from pivotal data toward first commercialization, but timing and package completeness still matter because the current thesis is heavily concentrated in azetukalner [#PR-2026-03-09] [#10-K-2026-02-26].
2027-06-30catalystMulti-indication execution beyond epilepsy remains the next leg of value creationHigh impact
Primary company updates still point to a broader azetukalner and pipeline buildout: X-TOLE3 and X-ACKT continue to enroll, X-NOVA2 topline data are expected in H1 2027, and Phase 1 pain programs XEN1701 and XEN1120 are expected to complete in 2026 to support Phase 2 proof-of-concept studies. This can broaden the story beyond a single epilepsy filing, but it is a longer-duration catalyst set with meaningful execution risk and limited near-term readout density [#PR-2026-02-26] [#10-K-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology